Astellas cuts a bispecific in cancer and a mitochondria-focused asset from Mitobridge deal
Astellas said it has removed a Phase 1 cancer asset as well as a small molecule that came from its Mitobridge acquisition.
The Japanese pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
